THE ROLE OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS AND PROINFLAMMATORY CYTOKINES IN THE PATHOGENETIC MECHANISMS OF THE CORONAVIRUS INFECTION (COVID-19)
Relevance: The similarity of the pathogenetic mechanisms of coronavirus infection (COVID-19) with autoimmune processes determinared the widespread use of genetically engineered biological drugs (GEBD) in the treatment of COVID-19. The current knowledge on the role of proinflammatory cytokines as interleukins (IL)1, 6 and inhibitors of tumor necrosis factor-α (TNF-α) is summarized, including their involvement into the pathogenetic mechanisms of coronavirus infection. Based on data of recent studies, we generalized the results of using GEBD in the treatment of varying severity COVID-19 and highlighted the features of their applying. The results of the "repositioned" biological drugs for the COVID-19 therapy were analyzed, and the practical experience of the appointment during the pandemic (including clinical studies) were reflected.
Aim: Analysis of literature related to on the experience of the international use of genetic engineering drugs in the treatment of coronavirus infection of varying severity.
Search strategy: The literature search was carried out using PubMed, GoogleScholar and Medline databases over the last 3 years. Medline databases over the past 3 years, and several sources from 1996. 2001 and 2009 containing conceptual information were also included. Inclusion criteria were reports on randomized and cohort studies, meta-analyses, systematic reviews, original full-text articles in English and Russian that are in the public domain and contain statistically confirmed findings. Exclusion criteria: brief reports, newspaper articles and personal communications.
Results: Based on the results of our review, many studies indicate a correlation between increased levels of pro-inflammatory markers such as interleukin (IL)6, IL8, IL10, IL2R, tumor necrosis factor α (TNF-α) and the severity of the COVID- 19. Despite on the widespread use of various mechanisms GEBD drugs with in the fight against the pandemic, the greatest effectiveness was demonstrated by IL-6 blockers/
Kristina S. Rutskaya-Moroshan1, Saule T. Abisheva1,
Tatyana V. Vinnik2, Bakyt A. Aubakirova3,
Aigerim Т. Ajtkazina3, Anilim B. Аbіsheva4, Pavel I. Rebrikov1
1 NJSC «Astana Medical University», Department of Family Medicine №1, Astana, Republic of Kazakhstan;
2 Ariel University, Ariel, Israel;
3 City Multidisciplinary Hospital No. 2, Astana, Republic of Kazakhstan;
4 City Polyclinic No. 9, Astana, Republic of Kazakhstan.
1 Аронова Е.С., Белов Б.С. Перспективы применения ингибиторов фактора некроза опухоли α у больных COVID-19 // Современная ревматология. 2021. №15(2). С. 89-93. doi.org/10.14412/1996-7012-2021-2-89-93
2. Белобородова Н.В., Зуев Е.В., Замятин М.Н., Гусаров В.Г. Этиотропная терапия COVID-19: критический анализ и перспективы // Общая реаниматология. 2020. №16(6). С. 65-90. https://doi.org/10.15360/1813-9779-2020-4-0-1
3. Насонов Е.Л., Лила А.М. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды // Научно-практическая ревматология. 2017. №55(6). С.590-599. doi.org/10.14412/1995-4484-2017-590-599.
4. Руцкая-Морошан К.С., Абишева С.Т., Лила А.М. Общность патогенетических аспектов, аутоиммунитета и фармакотерапии при коронавирусной инфекции (COVID-19) и иммуновоспалительных ревматических заболеваниях // Современная ревматология. 2022. № 16(5). С.82-87. doi.org/10.14412/1996-7012-2022-5-82-87
5. Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis // J Med Virol. 2020. №92(11): 2283–2285. doi: 10.1002/jmv.25948.
6. Bamias G., Kokkotis G., Christidou A., Christodoulou D.K. et al. The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD // Eur J Gastroenterol Hepatol. 2021. №33(1S Suppl 1): 810-817. doi: 10.1097/MEG.0000000000002267.
7. Bartoletti M., Azap O., Barac A., Bussini L. et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management // Clin Microbiol Infect. 2022. №28(2): р. 222-238. doi: 10.1016/j.cmi.2021.11.007
8. Brito C.A., Paiva J.G., Pimentel F.N., Guimarães R.S., Moreira M.R. COVID-19 in patients with rheumatological diseases treated with anti-TNF // Ann Rheum Dis. 2021. №80: e62. doi: 10.1136/annrheumdis-2020-218171
9. Cappello M., Busacca A., Guida L. The course of COVID-19 in inflammatory Bowel disease: protective role of TNF antagonists // Gastroenterology. 2021. №160: 1885-1886. doi: 10.1053/j.gastro.2020.06.087
10. Chamlagain R., Shah S., Sharma Paudel B. et al. Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review // Interdiscip Perspect Infect Dis. 2021. eCollection 2021: 8903435.
11. Chen L., Liu H.G., Liu W., Liu J. et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia // Zhonghua Jie. 2020. №6; 43(0):E005. doi:10.3760/cma.j.issn.1001-0939.2020.0005
12. Croft M. The role of TNF superfamily members in T-cell function and diseases // Nature Rev Immunol. 2009. Vol. 271№9: 85-89 doi: 10.1038/nri2526
13. Del Valle D.M., Kim-Schulze S., Huang H.H., Beckmann N.D., Nirenberg S., Wang B. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival // Nat Med. 2020. № 26: 1636–1643. doi: 10.1038/s41591-020-1051-9.
14. Della-Torre E., Campochiaro C. et al. Interleukin-6 blockade with sarilumab in severe COVID-19 with Pneumonia systemic hyperinflammation: an open-label cohort study// Ann Rheum Dis. 2020. № 79(10): 1277-1285. doi: 10.1136/annrheumdis-2020-218122
15. Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19. The REMAP-CAP COVID-19 Immune Modulation Therapy Domain Randomized Clinical Trial // Preprint at medRxiv. 2021. 21259133. doi.org/10.1101/2021.06.18.21259133
16. Fajgenbaum D.C., June C.H. Cytokine storm // N. Engl. J. Med. 2020. Vol. 383 №23: 2255–2273. doi:10.1056/NEJMra2026131
17. Fakharian A., Barati S., Mirenayat M., Rezaei M. et al. Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial // Int Immunopharmacol. 2021. № 99: 10796. doi: 10.1016/j.intimp.2021.107961.
18. Feldmann M., Maini R.N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned // Annu Rev Immunol. 2001. Vol. 163 №19:96-104 doi: 0.1146/annurev.immunol.19.1.163.
19. Fisher B.A., Veenith T., Slade D. et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial // Lancet Respir Med. 2022. №10(3): 255-266. doi: 10.1016/S2213-2600(21)00460-4.
20. Fragoulis G.E., Evangelatos G., Arida A. et al. Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic // Ann Rheum Dis. 2021. №80,4: 60-67 doi.org/10.1136/ annrheumdis- 2020- 217935
21. Gao Y., Li T., Han M., Li X., Wu D., Xu Y. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19 // J Med Virol. 2020. №92(7): 791-796. doi:10.1002/jmv.25770
22. Garcia P.D.W., Fumeaux T., Guerci P. et al., Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort // E. Clin. Med. 2020. №25: 100449. doi: 10.1016/j.eclinm.2020.100449
23. Gianfrancesco M., Hyrich K.L., Al-Adely S., Carmona L. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry // Ann Rheum Dis.2020. № 79: р 859–866. doi: 10.1136/annrheumdis-2020-217871
24. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure // Cell Host Microbe. 2020. №27: 992–1000. doi: 10.1016/j.chom.2020.04.009
25. Gritti G., Raimondi F., Ripamonti D. et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support // Leukemia. 2021. Vol. 35: 2710–2714. doi: 20048561v1
26. Guo Y., Hu K., Li Y., Lu C., Ling K., Cai C., Wang W., Ye D. Targeting TNF-α for COVID-19: Recent Advanced and Controversies // Front Public Health. 2022. №10: 833967. doi: 10.3389/fpubh.2022.833967
27. Herold T., Jurinovic V., Arnreich C. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19// J Allergy Clin Immunol. 2020. №146(1):128–136. doi: 10.1016/j.jaci.2020.05.008.
28. Keewan E., Beg S., Naser S.A. Anti-TNF-alpha agents modulate SARS-CoV-2 receptors and increase the risk of infection through notch-1 signaling // Front Immunol 2021. №12:641295. doi.org/ 10. 3389/ fimmu. 2021. 641295
29. Ko H.K., Yu W.K., Pan S.W. et al. Consensus statement and recommendations on the treatment of COVID-19 // J Chin Med Assoc. 2022. 85(1): 5-17. doi: 10.1097/JCMA.0000000000000617.
30. Koh D.H., Choi M., Ryoo S., Huh K. et al. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis // Emerg Microbes Infect. 2022. №11(1): 1154-1165. doi: 10.1080/22221751.2022.2059405.
31. Kridin K., Schonmann Y., Damiani G. et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study // Dermatol Ther. 2021. №34: e15003. doi. org/ 10. 1111/ dth. 15003
32. Kyriazopoulou E. et al. An open label trial of anakinra to prevent respiratory failure in COVID-19 // eLife. 2021. vol. 10: 66125. doi:10.7554/eLife.66125
33. Lee J.S., Park S., Jeong H.W., et al. Immunophenotyping of COVID19 and influenza highlights the role of type I interferons in development of severe COVID19 // Sci Immunol. 2020. Vol. 10 №5(49): 554. doi: 10.1126/sciimmunol.abd1554.
34. Lai W.Y., Wang J.W., Huang B.T., Lin E.P., Yang P.C. A Novel TNF-α-Targeting Aptamer for TNF-α-Mediated Acute Lung Injury and Acute Liver Failure // Theranostics. 2019. Vol. 28 № 9: 1741-1751. doi: 10.7150/thno.30972.
35. Landi L., Ravaglia C., Russo E., Cataleta P., et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19// Sci Rep. 2020. №10(1): 217. doi: 10.1038/s41598-020-78492-y.
36. Lau S., Lau C., Chan K.H. et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment // J Gen Virol. 2013. №94 (12): 2679-2690. doi: 10.1099/vir.0.055533-0.
37. Maude S.L., Barrett D., Teachey D.T. Managing cytokine release syndrome associated with novel T cell-engaging therapies // Cancer J. 2014. №20(2): 119-122. doi: 10.1097/PPO.0000000000000035.
38. Minozzi S., Bonovas S., Lytras T., Pecoraro V., et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis // Expert Opin Drug Saf. 2016. №15: 11-15. doi: 10.1080/14740338.2016.1240783.
39. Mikuls T.R., Johnson S.R., Fraenkel L., Arasaratnam R.J. et al. American College of rheumatology guidance for the management of adult patients with rheumatic disease during the COVID-19 pandemic // Arthritis Rheumatol. 2020. №72: 1241–1251. doi: 10.1002/art.41437
40. Mulchandani R., Lyngdoh T., Kakkar A.K. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis // Eur J Clin Invest. 2021. №5: 1-21. doi:10.3760/cma.j.issn.1001-0939.2020.0005
41. Narain Sonali et al. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm // Chest. 2021. Vol. 159(3): 933-948. doi.org/10.1016/j.chest.2020.09.275
42. National Institute of Health. Treatment guidelines for COVID. National Institute of Health. 2022. Available at: https://www.covid19treatmentguidelines.nih.gov.
43. Nikanjam M., Yang J., Capparelli E. Population pharmacokinetics of Siltuximab: impact of disease state // Cancer Chemother Pharmacol. 2019. №84(5): 993-1001. doi: 10.1007/s00280-019-03939-7.
44. O'Halloran J., Kedar E., Anstrom K.J., McCarthy M.W. et al. Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19 // medRxiv [Preprint]. 2022. 09.22.22280245. doi: 10.1101/2022.09.22.22280245.
45. Peng J., Fu M., Mei H., Zheng H. et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis // Rev Med Virol. 2022. №32(3): e2295. doi: 10.1002/rmv.2295.
46. Potere N., Batticciotto A., Vecchié A., Porreca E. et al. The role of IL-6 and IL-6 blockade in COVID-19 // Expert Rev Clin Immunol. 2021. №17(6): 601-618. doi: 10.1080/1744666X.2021.1919086.
47. Pan H., Peto R., Henao-Restrepo A.M., Preziosi M.P., Sathiyamoorthy V. et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results // N Engl J Med. 2021. №11 (6): 497-511. https://www.nejm.org/doi/full/10.1056/nejmoa2023184
48. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial // Lancet. 2021. Vol. 397: 1637–1645. doi: 10.1080/22221751.2022.2059405.
49. Rezaei Tolzali M.M., Noori M., Shokri P., Rahmani S., Khanzadeh S. et al. Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review // Rev Med Virol. 2022. №32(6): e2388. doi: 10.1002/rmv.2388.
50. Rivera-Rodriguez L., Pardo-Díaz E., Moreno-Espinosa S., Scheffler-Mendoza S. et al. Use of infliximab in the treatment of macrophage activation syndrome complicating Kawasaki disease // J Pediatr Hematol Oncol. 2021. № 43: 448–451. doi: 10.1097/MPH.0000000000001756
51. Rovina N., Akinosoglou K., Eugen-Olsen J., Hayek S., Reiser J., Giamarellos-Bourboulis E.J. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia // Crit Care. 2020. Vol. 24(1): 187. doi: 10.1186/s13054-020-02897-4.
52. Sarzi-Puttini P., Giorgi V., Sirotti S. et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? // Clin Exp Rheumatol. 2021. №38(2): 337-342. doi: 10.55563/clinexprheumatol/xcdary.
53. Shakoory B., Carcillo J.A., Chatham W.W., Amdur R.L. et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial // Crit Care Med. 2016. №44(2): 275-281. doi: 10.1097/CCM.0000000000001402.
54. Sims J.E., Smith D.E. The IL-1 family: regulators of immunity // Nat Rev Immunol. 2010. №10(2): 89-102. doi: 10.1038/nri2691
55. Tharaux P.L. et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial // Lancet Respir. Med. 2021. №9: 295–304. doi: 10.1016/S2213-2600(20)30556-7.
56. Ungaro R.C., Brenner E.J., Agrawal M. et al. Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry // Gastroenterology. 2022. №162(1): 316-319 doi: 10.1053/j.gastro.2021.09.011.
57. WHO coronavirus (COVID-19) dashboard WHO coronavirus (COVID-19) dashboard with vaccination data https://covid19.who.int. (Accepted: 25.10.2022)
58. Van de Veerdonk Ye.Q., Wang B., Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19 // J Infect. 2020. №80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
59. Wang Q., Liu J., Shao R. et al. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared wit h the general population: a systematic review and metaanalysis // Rheumatol Int. 2021. №41: 851–861. https:// doi. org/ 10. 1007/ s00296- 021- 04803-9
60. Wendling D., Prati C. Paradoxical effects of anti-TNF-a agents in inflammatory diseases // Expert Rev Clin Immunol. 2014. №10: 159–169. doi: 10.1586/1744666X.2014.866038
61. Xu X., Han M., Li T. et al. Effective treatment of COVID-19 patients with tocilizumab // Proc Natl Acad Sci USA. 2020. №117(20): 10970-10975. doi:10.1073/pnas.2005615117
62. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir Med. 2020. №8(4): 420–427. doi: 10.1016/S2213-2600(20)30076
63. Yang Y., Shen C., Li J., Yuan J., Yang M., Wang F., et al. Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome // medRxiv. 2020. №3(2). doi: 10.1101/2020.03.02.20029975
64. Zinkernagel R.M. Immunology taught by viruses // Science. 1996. №271: 173-178. doi: 10.1126/science.271.5246.173
References: [1-4]
1. Aronova E.S., Belov B.S. Perspektivy primeneniya ingibitorov faktora nekroza opukholi α u bol'nykh COVID-19 [The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19]. Sovremennaya revmatologiya [Modern Rheumatology Journal]. 2021. №15(2): 89-93. [In Russian]
2. Beloborodova N.V., Zuev E.V., Zamyatin M.N., Gusarov V.G. Etiotropnaya terapiya COVID-19: kriticheskii analiz i perspektivy [Causal Therapy of COVID-19: Critical Review and Prospects]. Obshchaya reanimatologiya [General Reanimatology]. 2020. №16(6): 65-90. https://doi.org/10.15360/1813-9779-2020-4-0-1 (Accepted: 16.06.2020) [in Russian]
3. Nasonov E.L., Lila A.M. Ingibitsiya interleikina 6 pri immunovospalitel'nykh revmaticheskikh zabolevaniyakh: dostizheniya, perspektivy i nadezhdy [Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes]. Nauchno-prakticheskaya revmatologiya [Rheumatology Science and Practice]. 2017. №55(6): 590-599 [In Russian].
4. Rutskaya-Moroshan K.S., Abisheva S.T., Lila A.M. Obshchnost' patogeneticheskikh aspektov, autoimmuniteta i farmakoterapii pri koronavirusnoi infektsii (COVID-19) i immunovospalitel'nykh revmaticheskikh zabolevaniyakh [Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases]. Sovremennaya revmatologiya [Modern Rheumatology Journal]. 2022. №16(5): 82-87. [in Russian].
Number of Views: 80
Category of articles:
COVID-19 - Topical Subject
Bibliography link
Rutskaya-Moroshan K.S., Abisheva S.T., Vinnik T.V., Aubakirova B.A., Ajtkazina А.Т., Аbіsheva A.B., Rebrikov P.I. The role of genetically engineered biological agents and proinflammatory cytokines in the pathogenetic mechanisms of the coronavirus infection (COVID-19) // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 4, pp. 13-23. doi 10.34689/SH.2023.25.4.002Related publications:
IMMUNOLOGICAL CHANGES IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2
EFFICACY OF THE ANTIVIRAL DRUG ENISAMY IODIDE IN SEVERE ADULT ACUTE RESPIRATORY INFECTIONS IN THE COVID-19 ERA
APPLICATION OF ARTIFICIAL INTELLIGENCE IN COMBATING THE COVID-19 PANDEMIC: CURRENT TRENDS AND PROSPECTS. REVIEW
CONSEQUENCES OF THE CORONAVIRUS INFECTION: THE POST-COVID SYNDROME AND MENTAL MANIFESTATIONS. LITERATURE REVIEW
FEATURES OF THE SICKNESS BEHAVIOR OF ARTERIAL HYPERTENSION AND OBESITY DURING THE PANDEMIC OF COVID-19 CORONAVIRUS. REVIEW